Our 2022, step by step

We close a very intense year that marked significant steps forward in the development of the first cellular therapy for the treatment of acute spinal cord injuries.

Hemera has grown and been enriched with new skills, expanding the clinical board and the management team. We increased strategic collaborations that have given a strong acceleration towards the goal of bringing our therapy to the patient in the shortest possible time.

Capital raising has exceeded 2 million and Hemera is confidently looking to the challenges of next year which will open with a new investment round and will see the entry of international talents.